MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-21-2026
Sol-Gel Technologies Ltd. Total Shareholders Equity 2011-2026 | SLGL
Annual Total Shareholders Equity Sol-Gel Technologies Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.8 M | 28.8 M | 38.6 M | 42.2 M | 55.6 M | 50.8 M | 52.5 M | 63.9 M | -52.7 M | -31.3 M | -11.5 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 63.9 M | -52.7 M | 23.6 M |
Quarterly Total Shareholders Equity Sol-Gel Technologies Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 55.6 M | - | 39.2 M | 47.1 M | 50.8 M | - | 65.5 M | 67.1 M | 52.5 M | - | 54.7 M | - | 63.9 M | - | 81.5 M | - | -52.7 M | - | - | - | -31.3 M | - | - | - | -11.5 M | - | - | - | -2.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 81.5 M | -52.7 M | 34.3 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Amgen
AMGN
|
8.66 B | $ 349.36 | 2.75 % | $ 188 B | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-70.8 M | $ 12.67 | 2.82 % | $ 3.97 B | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 24.45 | 5.07 % | $ 3.11 B | USA |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
94.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
15.6 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.47 | 8.17 % | $ 391 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.83 | 1.86 % | $ 9.21 B |  Australia |
 |
BioNTech SE
BNTX
|
1.37 B | $ 91.3 | 1.87 % | $ 27.2 B | Germany |
 |
CymaBay Therapeutics
CBAY
|
292 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
19 M | $ 2.72 | 5.84 % | $ 17.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.7 B | $ 4.59 | 0.88 % | $ 742 M | Britain |
 |
Avid Bioservices
CDMO
|
60.9 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
163 M | - | - | $ 1.41 B | USA |
 |
Cabaletta Bio
CABA
|
112 M | $ 3.07 | - | $ 308 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.44 M | $ 3.08 | 1.65 % | $ 6.7 B | Israel |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
64.2 M | $ 1.93 | 4.89 % | $ 368 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
112 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-17.6 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
6.84 M | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
8.54 M | $ 2.82 | 2.55 % | $ 7.36 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
351 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
597 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Cyclerion Therapeutics
CYCN
|
8.85 M | $ 3.47 | -0.29 % | $ 8.74 M | USA |